Cholecystokinin
In clinical developmentAlso known as CCK-PZ, CCK-PZ - Cholecystokinin-pancreozymin, Cholecystokinin-pancreozymin, PZ - Pancreozymin+3 more
CCK-PZ, CCK-PZ - Cholecystokinin-pancreozymin, Cholecystokinin-pancreozymin, PZ - Pancreozymin, Pancreozymin, cholecystokinin, human, pancreozymin (cholecystokinin).
Recent clinical, regulatory, research and industry developments relating to this drug.
Cholecystokinin Modulates Corticostriatal Transmission and Plasticity in Rodents.
Effect of Bile Acid Secretion and Sequestration on GLP-1 Secretion
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- The Journal of neuroscience : the official journal of the Society for Neuroscience2
- eLife1
- eNeuro1
- Freund TF2
- Katona I2
- Mackie K2
- Acsady L1
- Aiznkot T1
- Cohen O1
- Fontanaud P1
- Golan M1
- Institute of Experimental Medicine2
- Hebrew University of Jerusalem1
- Institute of Animal Sciences1
- Institute of Functional Genomics1
- Instituto de Neurociencias UMH-CSIC1
- Nantes Université1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Frequently co-studied with Cholecystokinin in the research literature.
Frequently co-studied with Cholecystokinin in the research literature.
Frequently co-studied with Cholecystokinin in the research literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials